Design, Synthesis, and Biological Evaluation of Quercetagetin Analogues as JNK1 Inhibitors
作者:Judith Hierold、Sohee Baek、Rene Rieger、Tae-Gyu Lim、Saman Zakpur、Marcelino Arciniega、Ki Won Lee、Robert Huber、Lutz F. Tietze
DOI:10.1002/chem.201502475
日期:2015.11.16
recent discovery of c‐Jun NH2‐terminal kinase JNK1 suppression by natural quercetagetin (1) is a promising lead for the development of novel anticancer agents. Using both X‐ray structure and docking analyses we predicted that 5′‐hydroxy‐ (2) and 5′‐hydroxymethyl‐quercetagetin (3) would inhibit JNK1 more actively than the parent compound 1. Notably, our drug design was based on the active enzyme–ligand complex
天然槲皮素(1)抑制c-Jun NH 2末端激酶JNK1的最新发现为新型抗癌药的开发提供了有希望的线索。使用X射线结构和对接分析,我们预测5'-羟基-(2)和5'-羟甲基-槲皮素(3)会比母体化合物1更有效地抑制JNK1 。值得注意的是,我们的药物设计基于活性酶-配体复合物,而不是酶的相对开放的载脂蛋白结构。在本文中,我们通过对接模型实验测试了我们的理论预测,并报告了槲皮素类似物2和3的首次合成和生物学评估。。如所计算的,两种化合物均强烈抑制JNK1活性。该IC 50测定值为3.4μ中号和12.2μ中号,分别,这表明2超过母体化合物的效力1(IC 50 = 4.6μ中号)。化合物2还显示出在紫外线照射后以高特异性抑制基质金属蛋白酶-1的表达。